Ucb SA
Health Care
Current price
Target price 00%
Ranks rating
76
Position in sub-industry
1148 / 1328
Position in country
158 / 173
Return on Assets, %
2.1
-2.7
Net income margin, %
1.2
2.8
EBITDA margin, %
20.5
10.8
Debt to Equity, %
33.8
19.2
Intangible assets and goodwill, %
61
3.6
Revenue CAGR 3Y, %
-0.6
8.5
Revenue Y, % chg
-1.4
0.5
P/E
68.5
22.7
P/BV
2.5
1.5
P/S
4.4
2.3
EV/S
4.8
2.4
EV/EBITDA
21.1
7.4
Average Analyst recommendation
Hold
Hold
Average upside forecasts, %
8
51.3
Forward P/E
24.5
15.6
Dividend Yield, %
1.1
1.7
Forward Dividend Yield, %
1.1
0.2
Expected dividend per share
0.7
0
Payout Ratio, %
73.5
30.3
Dividend Ex Date
2023-05-01
Competitors
Ranks
-
Novo Nordisk A/S
00%
-
AstraZeneca PLC
00%
-
Eli Lilly and Co
00%
-
Roche Holding AG
00%
-
Novartis AG
00%
-
Financiere de Tubize SA
00%
-
Johnson & Johnson
00%
-
Merck & Co Inc
00%
-
Ucb SA
00%
-
Pfizer Inc
00%
Ready-made portfolio of the best Russian stocks
- Created by artificial intelligence
- Verified by analysts
- Available even to beginners
Company information
Country
Belgium
Sector
Health Care
Industry group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Pharmaceuticals
Sub-sector
Health Care
Capitalization (millions of $)
25166
Ticker
UCBJY.PK
ISIN
US9034801012
IPO date
1987-01-02
Availability on Russian exchanges
No
Reporting for
2024-02-28
Date fact. publication of reports
2023-12-31
Company Description
Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.
A step towards better analytics
- find the best promotions through the Screener
- keep an eye on stock valuation
- download detailed reports
and much more after free registration
RegistrationMore convenient from your phone? Download: